On April 8th, 2020,Guangdong Raffles PharmaTech Co.,Ltd and Anhui Xuancheng Menovo Pharmaceutical Co., Ltd. signed a strategic cooperation agreement for small molecule innovation medicine process development and manufacturing.
It is agreed that Raffles shall develop synthetic routes and conduct processes and scale-up research for new drug intermediates, and Menovo shall undertake the large-scale production.
At the signing ceremony, Andrew Phillis -VP of BD Raffles, highlighted the signing of the strategic cooperation agreement is the starting point for the two sides to forge ahead and deepen strategic cooperation.
Shi jianxiang, Director and VP of Menovo, emphasized that Menovo has first-class production equipment and professional team will provide strong foundation for the strategic cooperation between the two sides. Through the cooperation with Raffles, we will introduce more high-value-added products and continue to participate in the R&D and production of innovative drugs.